Tirzepatides unique approach: Tirzepatide goes a step further by targeting two hormones, GLP1 and another called GIP
about the width of a quarter
2008-A APPLICATION OF LIVERFAST BIOMARKERS TO PREDICT STEATOSIS IN CHRONIC HEPATITIS B PATIENTS WITH METABOLIC SYNDROME Mati Ullah Dad Ullah 1 , Mansoor Rahman 1 , Mehdi Sakka 2 , Rana Alkouri 2 , Muhammad Asad Raza 1 , Mukarram Jamat Ali 1 , Karen Campoverde Reyes 1 , Maxime Deregnaucourt 2 , Dominique Bonnefont-Rousselot 2,3 , Ronald Quiambao 4 , Mona Munteanu 4 and Daryl T
Titration: Follow the dosage escalation schedule, titrating every 30 days to achieve the maintenance dosage
The core of the treatment typically involves weekly subcutaneous injections, though select oral GLP-1 options are available for specific patient profiles